查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470987

肝纖維化藥物市場：按藥物類型、分銷管道分類 - 全球預測 2024-2030

Liver Fibrosis Drugs Market by Drug Type (Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs), Distribution Channel (Offline Pharmacies, Online Pharmacies) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

肝纖維化藥物市場規模預計2023年為142.8億美元，預計2024年將達155.7億美元，2030年將達273.8億美元，複合年成長率為9.74%。

肝纖維化藥物是一種旨在預防、阻止或逆轉肝纖維化過程的藥物。肝纖維化是一種以細胞外基質蛋白（包括膠原蛋白）過度累積為特徵的疾病，導致肝組織形成疤痕。如果不及時治療，這種情況可能會發展為更嚴重的肝臟疾病，例如肝硬化和肝癌。這些藥物旨在破壞纖維化過程、減少發炎和改善肝功能。乙型肝炎、丙型肝炎、非酒精性脂肪性肝炎 (NASH) 和酒精性肝病的盛行率不斷上升，強調了對有效治療方法的需求，包括治療肝纖維化的藥物。製藥公司和研究機構增加投資開發新療法正在擴大肝纖維化治療的發展。肝纖維化治療藥物的高開發和生產成本阻礙了市場成長。市場成長是由旨在對抗肝病和促進肝臟健康的國際醫療保健計劃的提供以及對肝纖維化研究和藥物開發的認知和資金的增加所推動的，預計將為肝纖維化研究和藥物開發創造機會。

主要市場統計
基準年[2023] 142.8億美元
預測年份 [2024] 155.7億美元
預測年份 [2030] 273.8億美元
複合年成長率（%） 9.74%

藥物類型 擴大抗纖維化藥物的使用以預防和抑制纖維化

抗纖維化藥物是專門設計用於預防或減少肝臟纖維化（疤痕）形成的藥物。這些藥物透過針對參與細胞外基質蛋白累積的途徑發揮作用，從而減緩或逆轉纖維化過程。這些藥物對於治療導致肝纖維化的疾病至關重要，並有可能阻止肝硬化和肝功能衰竭的進展。抗氧化發炎調節劑是作用於肝臟內氧化壓力和發炎途徑的藥物。氧化壓力和發炎是肝纖維化的主要促進要素，並導致肝損傷的進展。透過調節這些途徑，這些藥物旨在保護肝臟免受進一步損傷，阻止纖維化過程，並在某些情況下促進現有纖維化的解決。抗病毒藥物在肝纖維化的治療中發揮重要作用，特別是當纖維化是由B型肝炎或C型肝炎等病毒感染引起時。透過有效控制或根除病毒感染，這些藥物可以防止引起纖維化的持續肝損傷，並降低嚴重肝臟疾病（包括肝硬化和肝癌）的風險。免疫調節藥物是一種影響免疫系統反應並促進肝纖維化發生和進展的藥物。這些藥物可以增強或抑制免疫反應的特定成分，旨在減少肝臟的發炎和纖維化活動。其確切作用取決於纖維化的根本原因，使其成為標靶治療策略的重要組成部分。

分銷管道 透過網路藥房的 24/7 服務改善肝纖維化藥物的獲取

線下藥局構成了肝纖維化藥物的基本分銷管道。這些藥局位於社區內或社區附近，患者可以輕鬆前往。線下藥局，包括獨立藥局和連鎖藥局，提供個人化服務和快速取得藥物，使其成為許多尋求立即治療的患者的首選。醫院藥房專門為醫院和臨床環境中的住院患者和門診病人配藥。它在分發肝纖維化藥物方面發揮著重要作用，特別是對於接受直接醫療護理或需要特定治療的患者。醫院藥局滿足接受醫療管理的肝纖維化患者的特殊需求，並確保及時、準確的藥物傳遞。零售藥局，包括大型藥局連鎖店和設有藥局部門的超級市場，提供廣泛的網路來改善藥品的取得。零售藥局提供多種藥品，可供廣大民眾使用。零售藥局利用其廣泛的影響力和營運效率，為分銷網路做出了重大貢獻。網路藥局已成為肝纖維化藥物不斷成長的分銷管道，提供便利且價格往往具有競爭力。網路藥局迎合那些喜歡將藥物直接送到家中的患者，無需前往實體店。網路藥局對於行動不便或居住在偏遠地區的患者特別有利。

區域洞察

美洲，特別是北美，是肝纖維化藥物開發和採用的關鍵地區。美洲是醫藥創新、法律規範和醫療保健支出的關鍵地區，使其成為肝纖維化藥物的主要市場。由於肥胖和飲酒等因素，肝病的高盛行率進一步增加了該地區對有效治療方法的需求。此外，政府和私營部門對肝病研究的大力支持正在支持肝纖維化新的先進治療方法的開發。由於醫療保健支出的增加、對肝病的認知不斷提高以及醫療保健基礎設施的改善，亞太地區肝纖維化藥物市場正在快速成長。日本、中國、韓國等國家位居前列，其中日本憑藉先進的醫療體系和較高的藥物研發率做出了重大貢獻。乙型肝炎和丙型肝炎是肝纖維化的主要危險因素，該地區的盛行率相對較高，迫切需要有效的治療方案。此外，不斷成長的中等收入群體越來越有能力負擔先進的治療方法，從而推動了亞太地區肝纖維化藥物市場的發展。歐洲、中東和非洲地區的肝纖維化治療市場呈現多樣化的前景。歐洲的特點是強力的法律規範、廣泛的醫療保健以及對肝病的高度認知，使其成為這些治療方法的主要市場。歐洲肝病研究協會 (EASL)舉措正在加強肝纖維化治療的前景，進一步提高研究和意識。中東一些國家正在發展醫療基礎設施，這可能會擴大肝纖維化治療的範圍。非洲市場的成長受到經濟限制的阻礙，但國際衛生組織正在加緊努力，透過教育和治療計劃來改善狀況。

FPNV定位矩陣

FPNV定位矩陣對於評估肝纖維化藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對肝纖維化治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.肝纖維化治療藥物市場規模及預測如何？

2.肝纖維化藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.肝纖維化藥物市場的技術趨勢和法規結構是什麼？

4.肝纖維化治療藥物市場主要廠商的市場佔有率如何？

5.進入肝纖維化藥物市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球慢性肝病盛行率增加
      • 肝纖維化治療優惠報銷政策
    • 抑制因素
      • 配製和開發肝纖維化藥物的複雜性
    • 機會
      • 用於新開發的新研究基金
      • 改良肝臟影像技術和肝纖維化生物標記
    • 任務
      • 肝纖維化藥物核准的嚴格法規結構
  • 市場區隔分析
    • 藥物類型：增加抗纖維化藥物的使用，預防和減少纖維化的形成
    • 分銷管道：網上藥房的24/7服務改善了肝纖維化藥物的獲取
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章依藥物類型分類的肝纖維化治療藥物市場

  • 抗纖維化劑
  • 抗氧化發炎調節劑
  • 抗病毒藥物
  • 免疫調節劑

第7章肝纖維化治療藥物市場：依通路分類

  • 線下藥局
  • 網路藥房

第8章北美和南美肝纖維化治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區肝纖維化藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲肝纖維化治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 伺服 2 期試驗顯示，83% 接受治療的成年人在 MASH 肝病方面取得了突破性成果，纖維化顯著改善。
    • 益普生宣布，美國FDA 已對其治療罕見膽汁淤積性肝病的藥物Elafibranor的新藥申請給予優先審查。
    • Madrigal Pharmaceuticals 宣布 Resmetirom 新藥申請獲得 NDA 接受和優先審查，Resmetirom 是一種治療與肝纖維化相關的 NASH 的藥物
  • 戰略分析和建議

第12章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-437A5D08AE2D

[196 Pages Report] The Liver Fibrosis Drugs Market size was estimated at USD 14.28 billion in 2023 and expected to reach USD 15.57 billion in 2024, at a CAGR 9.74% to reach USD 27.38 billion by 2030.

Liver fibrosis drugs are pharmaceutical agents designed to prevent, halt, or reverse the process of liver fibrosis. Liver fibrosis itself is a pathological condition characterized by the excessive accumulation of extracellular matrix proteins, including collagen, which leads to the scarring of liver tissue. This condition can progress to more severe forms of liver disease, such as cirrhosis and liver cancer if left untreated. These drugs aim to disrupt the fibrogenic processes, mitigate inflammation, and improve liver function. The rising incidence of conditions such as hepatitis B and C, non-alcoholic steatohepatitis (NASH), and alcoholic liver disease fuels the need for effective treatments, including liver fibrosis drugs. Rising investments by pharmaceutical companies and research institutions for developing novel therapeutics are expanding the development of liver fibrosis drugs. The high development and production costs of liver fibrosis drugs hamper the growth of the market. The availability of international healthcare programs aimed at combating liver diseases and promoting liver health with increasing awareness and funding for liver fibrosis research and drug development are expected to create opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 14.28 billion
Estimated Year [2024] USD 15.57 billion
Forecast Year [2030] USD 27.38 billion
CAGR (%) 9.74%

Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis

Antifibrotic agents are specifically designed to prevent and reduce the formation of fibrosis (scarring) in the liver. These drugs work by targeting the pathways involved in the accumulation of extracellular matrix proteins, thereby slowing down or reversing the fibrotic process. They are vital in managing diseases that lead to liver fibrosis, offering a potential means to halt the progression towards cirrhosis and liver failure. Antioxidant inflammation modulators are drugs that act on the oxidative stress and inflammatory pathways within the liver. Oxidative stress and inflammation are key drivers of liver fibrosis, contributing to the progression of liver injury. By modulating these pathways, these agents aim to protect the liver from further damage, halt the fibrotic process, and, in some instances, promote the resolution of existing fibrosis. Antiviral drugs play a crucial role in the management of liver fibrosis, particularly in cases where the fibrosis is caused by viral infections such as Hepatitis B and Hepatitis C. By effectively controlling or eradicating the viral infection, these drugs prevent the ongoing liver damage that triggers fibrosis, thereby reducing the risk of developing severe liver conditions including, cirrhosis or liver cancer. Immune modulators are drugs that influence the immune system's response and contribute to the development and progression of liver fibrosis. These drugs can either enhance or suppress specific components of the immune response, aiming to reduce the inflammatory and fibrogenic activity in the liver. Their precise role varies depending on the underlying cause of fibrosis, making them a critical component of a targeted therapeutic strategy.

Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services

Offline pharmacies constitute a fundamental distribution channel for liver fibrosis drugs. They are located within or near community settings, providing easy access for patients. Offline pharmacies, including independent and chain pharmacies, offer personalized services and immediate drug availability, making them a preferred option for many patients seeking immediate treatment. Hospital pharmacies specialize in dispensing medications to inpatients and outpatients within a hospital or clinical setting. They play a critical role in the distribution of liver fibrosis drugs, especially for patients receiving direct medical care or those with specific therapeutic needs. Hospital pharmacies ensure the timely and accurate provision of medications, catering to the specialized needs of liver fibrosis patients under medical supervision. Retail pharmacies, including large pharmacy chains and supermarkets with pharmacy departments, offer extensive networks that enhance drug accessibility. They provide liver fibrosis drugs among a wide range of pharmaceutical products, ensuring availability for a broad demographic. Retail pharmacies contribute significantly to the distribution network by leveraging their extensive presence and operational efficiencies. Online pharmacies have emerged as a growing distribution channel for liver fibrosis drugs, offering convenience and often competitive pricing. They cater to patients who prefer having their medications delivered directly to their homes, eliminating the need for physical store visits. Online pharmacies are particularly beneficial for patients with mobility issues or those living in remote areas.

Regional Insights

The Americas, particularly North America, stands as a pivotal region in the development and adoption of liver fibrosis drugs. The Americas represents a significant region in pharmaceutical innovation, regulatory frameworks, and health spending, making it a primary market for liver fibrosis therapies. The high prevalence of liver diseases due to factors such as obesity and alcohol consumption further drives the need for effective treatments in this region. Additionally, strong support for liver disease research from both government and private sectors bolsters the development of new and advanced treatments for liver fibrosis. The Asia-Pacific region is witnessing rapid growth in the liver fibrosis drug market, attributed to increasing healthcare expenditure, growing awareness of liver diseases, and improving healthcare infrastructure. Countries such as Japan, China, and South Korea are at the forefront, with Japan being a significant contributor due to its advanced healthcare system and high rate of pharmaceutical R&D. The prevalence of hepatitis B and C, major risk factors for liver fibrosis, is relatively high in this region, driving the urgency for effective treatment options. Moreover, the expanding middle-class population is increasingly able to afford advanced therapies, thereby boosting the market for liver fibrosis drugs in APAC. The EMEA region presents a diverse outlook on the market for liver fibrosis drugs. Europe is characterized by its strong regulatory frameworks, widespread healthcare access, and high awareness of liver conditions, making it a major market for these therapies. Initiatives by the European Association for the Study of the Liver (EASL) further support research and awareness, enhancing the landscape for liver fibrosis treatment. Certain countries in the Middle East are witnessing growth in healthcare infrastructure, which could lead to increased access to liver fibrosis drugs. Africa's market growth is hindered by economic constraints, but international health organizations are stepping in to improve the situation through educational and treatment programs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Liver Fibrosis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liver Fibrosis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Liver Fibrosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Arbutus Biopharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hepion Pharmaceuticals, Inc., Inventiva S.A., LG Life Science Ltd., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Mirum Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pharmaxis Limited, and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Liver Fibrosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Antifibrotic Agents
    • Antioxidant Inflammation Modulators
    • Antiviral Drugs
    • Immune Modulators
  • Distribution Channel
    • Offline Pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Liver Fibrosis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liver Fibrosis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Liver Fibrosis Drugs Market?

4. What is the market share of the leading vendors in the Liver Fibrosis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Liver Fibrosis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic liver diseases worldwide
      • 5.1.1.2. Favorable reimbursement policies for treatment of liver fibrosis
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity in formulation and development of liver fibrosis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging research funding for the development of novel liver fibrosis drugs
      • 5.1.3.2. Improvements in liver imaging techniques and biomarkers for liver fibrosis
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks for drug approval of liver fibrosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis
    • 5.2.2. Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Liver Fibrosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antifibrotic Agents
  • 6.3. Antioxidant Inflammation Modulators
  • 6.4. Antiviral Drugs
  • 6.5. Immune Modulators

7. Liver Fibrosis Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Offline Pharmacies
  • 7.3. Online Pharmacies

8. Americas Liver Fibrosis Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Liver Fibrosis Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Liver Fibrosis Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis
    • 11.3.2. Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease
    • 11.3.3. Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. LIVER FIBROSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. LIVER FIBROSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. LIVER FIBROSIS DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 283. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023